Bingham Osborn & Scarborough’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-5,566
| Closed | -$600K | – | 2 |
|
|
2021
Q3 | $600K | Sell |
5,566
-775
| -12% | -$88.6K | 0.04% | 73 |
|
|
2021
Q2 | $714K | Buy |
6,341
+1,064
| +20% | +$120K | 0.05% | 65 |
|
|
2021
Q1 | $571K | Buy |
5,277
+148
| +3% | +$15.8K | 0.04% | 70 |
|
|
2020
Q4 | $550K | Sell |
5,129
-14,044
| -73% | -$1.35M | 0.04% | 65 |
|
|
2020
Q3 | $1.68M | Buy |
19,173
+229
| +1% | +$21.6K | 0.13% | 46 |
|
|
2020
Q2 | $1.86M | Sell |
18,944
-1,260
| -6% | -$111K | 0.15% | 40 |
|
|
2020
Q1 | $1.54M | Sell |
20,204
-2,652
| -12% | -$226K | 0.15% | 40 |
|
|
2019
Q4 | $2.02M | Buy |
22,856
+171
| +0.8% | +$14.2K | 0.17% | 37 |
|
|
2019
Q3 | $1.72M | Sell |
22,685
-43
| -0.2% | -$2.95K | 0.15% | 37 |
|
|
2019
Q2 | $1.65M | Sell |
22,728
-1,193
| -5% | -$93.8K | 0.15% | 35 |
|
|
2019
Q1 | $1.93M | Sell |
23,921
-1,170
| -5% | -$95.7K | 0.18% | 34 |
|
|
2018
Q4 | $2.31M | Buy |
25,091
+507
| +2% | +$44.6K | 0.24% | 30 |
|
|
2018
Q3 | $2.33M | Sell |
24,584
-2,975
| -11% | -$282K | 0.21% | 34 |
|
|
2018
Q2 | $2.55M | Sell |
27,559
-7,602
| -22% | -$742K | 0.24% | 33 |
|
|
2018
Q1 | $3.33M | Buy |
35,161
+3,886
| +12% | +$427K | 0.31% | 27 |
|
|
2017
Q4 | $3.02M | Buy |
31,275
+10,207
| +48% | +$962K | 0.28% | 27 |
|
|
2017
Q3 | $1.87M | Sell |
21,068
-51
| -0.2% | -$3.88K | 0.18% | 33 |
|
|
2017
Q2 | $1.53M | Buy |
21,119
+1,754
| +9% | +$118K | 0.15% | 33 |
|
|
2017
Q1 | $1.26M | Buy |
19,365
+1,237
| +7% | +$77.8K | 0.12% | 36 |
|
|
2016
Q4 | $1.14M | Sell |
18,128
-853
| -4% | -$52.1K | 0.12% | 38 |
|
|
2016
Q3 | $1.2M | Buy |
18,981
+476
| +3% | +$30.8K | 0.13% | 39 |
|
|
2016
Q2 | $1.15M | Buy |
18,505
+114
| +0.6% | +$6.95K | 0.13% | 39 |
|
|
2016
Q1 | $1.05M | Buy |
18,391
+89
| +0.5% | +$4.96K | 0.12% | 40 |
|
|
2015
Q4 | $1.08M | Sell |
18,302
-358
| -2% | -$20.6K | 0.13% | 41 |
|
|
2015
Q3 | $1.01M | Buy |
18,660
+3,297
| +21% | +$215K | 0.13% | 41 |
|
|
2015
Q2 | $1.03M | Buy |
15,363
+121
| +0.8% | +$7.9K | 0.12% | 38 |
|
|
2015
Q1 | $892K | Hold |
15,242
| – | – | 0.11% | 43 |
|
|
2014
Q4 | $997K | Sell |
15,242
-64
| -0.4% | -$4.04K | 0.12% | 41 |
|
|
2014
Q3 | $884K | Hold |
15,306
| – | – | 0.11% | 42 |
|
|
2014
Q2 | $864K | Sell |
15,306
-138
| -0.9% | -$7.24K | 0.11% | 37 |
|
|
2014
Q1 | $794K | Sell |
15,444
-650
| -4% | -$32.9K | 0.11% | 39 |
|
|
2013
Q4 | $850K | Buy |
16,094
+752
| +5% | +$37K | 0.12% | 37 |
|
|
2013
Q3 | $686K | Buy |
15,342
+1,367
| +10% | +$60.6K | 0.11% | 44 |
|
|
2013
Q2 | $578K | Buy |
+13,975
| New | +$611K | 0.1% | 44 |
|
Other funds holding ABBV
Bingham Osborn & Scarborough's ABBV Position: Q4 2021 in Review
Bingham Osborn & Scarborough sold out of AbbVie (ABBV) in Q4 2021, closing a stake of 5,566 shares — an estimated $600K sold.
Bingham Osborn & Scarborough first reported a position in ABBV in Q2 2013 and held it in 34 quarters. The position peaked at $3.33M in Q1 2018. 2,981 funds tracked by Wall St. Rank hold ABBV as of Q4 2021.
- Bingham Osborn & Scarborough reported no remaining AbbVie position as of Q4 2021 after selling out during the quarter.
- Bingham Osborn & Scarborough sold 5,566 AbbVie shares in Q4 2021, an estimated $600K.
- Bingham Osborn & Scarborough first reported a position in AbbVie in Q2 2013 and held it in 34 quarters.
- Bingham Osborn & Scarborough's AbbVie position peaked at $3.33M in Q1 2018.
- 2,981 funds tracked by Wall St. Rank held AbbVie as of Q4 2021.
Based on Bingham Osborn & Scarborough's 13F filing for Q4 2021.